Epothilones in breast cancer: Review of clinical experience

Annals of Oncology

Volumn 18, Issue SUPPL. 5, 2007, Pages

  Fornier, M N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Epothilone; Ixabepilone; KOS 862; Metastatic breast cancer; Phase II clinical trial; Taxane resistant

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPOTHILONE D; EPOTHILONE DERIVATIVE; IXABEPILONE; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TUBULIN MODULATOR;

ABDOMINAL PAIN; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BACKACHE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; EXPERIENCE; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; HYPESTHESIA; LEUKOPENIA; LOADING DRUG DOSE; MEDLINE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SENSORY NEUROPATHY; STOMATITIS; WEAKNESS; ADJUVANT THERAPY; BREAST TUMOR; DRUG COMBINATION; FEMALE; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; EPOTHILONES; FEMALE; HUMANS; NEOADJUVANT THERAPY; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 38449123444     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm174     Document Type: Conference Paper

References (29)

1. Rowinsky EK, Calvo E. Novel agents that target tubulin and related elements. Semin Oncol 2006; 33: 421-435.
2. Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res 2003; 63: 6026-6031.
3. Kolman A. Activity of epothilones. Curr Opin Investig Drugs 2005; 6: 616-622.
4. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol®). J Biol Chem 1997; 272: 2534-2541.
5. Hari M, Loganzo F, Annable T et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006; 5: 270-278.
6. Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003; 21: 1866-1873.
7. Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004; 10: 1289-1298.
8. Piro LD, Rosen LS, Parson M et al. KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies. J Clin Oncol 2003; 22: 135 (Abstr 539).
9. Conte P, Thomas E, Martin M et al. Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC). J Clin Oncol 2006; 24 (Suppl): 568s (Abstr 10505).
10. Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23: 2726-2734.
11. Roche HH, Yelle L, Peck R. Efficacy results of a phase II study of ixabepilone in patients with metastatic breast cancer previously treated with an anthracycline (Abstr 96-93). Presented at the International Union Against World Cancer World Congress, Washington, DC, 8-12 July 2006; http://2006.confex.com/uicc/techprogram/P8062.HTM (10 January 2007, date last accessed).
12. Thomas E, Perez EA, Mukhopadhyay P et al. Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine. J Clin Oncol 2006; 24 (Suppl): 42s (Abstr 660).
13. Fornier MN, Martin M, Klimovsky J, Bunnell C. Manageable safety profile in patients with taxane-resistant metastatic breast cancer (MBC) treated with ixabepilone: Final report. J Clin Oncol 2006; 24 (Suppl): 575s (Abstr 10587).
14. Overmoyer B, Waintraub S, Kaufman PA et al. Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol 2005; 23 (Suppl): 72s (Abstr 778).
15. Baselga G, Gianni L, Llombart A et al. Predicting response to ixabepilone: Genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res Treat 2005; 94: S31-S32.
16. Llombart Cussac A, Baselga J, Manikhas G et al. Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data. J Clin Oncol 2005; 23 (Suppl): 25s (Abstr 586).
17. Amat S, Bougnoux P, Penault-Llorca F et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 2003; 88: 1339-1345.
18. Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17: 3412-3417.
19. Estevez LG, Cuevas JM, Anton A et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003; 9: 686-692.
20. Fisher B, Bryant J et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
21. Gradishar WJ, Wedam SB, Jahanzeb M et al. Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 2005; 16: 1297-1304.
22. Bunnell CA, Klinovsky J, Thomas E. Final efficacy results of a phase I/ II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a ataxane and an anthracycline. J Clin Oncol 2006; 24 (Suppl): 568s (Abstr 10511).
23. Vahdat T, Klimovsky J, Bunnell C. Phase I/II trial in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline: Final safety data. J Clin Oncol 2006; 24 (Suppl): 570s (Abstr 10528).
24. Cortes J, Climent MA, Gomez P et al. Phase I trial of weekly combination KOS-862 (epothilone D) and trastuzumab in HER-2 overexpressing malignancies. J Clin Oncol 2006; 24 (Suppl): 86s (Abstr 2028).
25. Larkin JM, Kaye SB. Epothilones in the treatment of cancer. Expert Opin Investig Drugs 2006; 15: 691-702.
26. Lee JJ, Low JA, Croarkin E et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol 2006; 24: 2084-2091.
27. Mielke S, Sparreboorn A, Mross K. Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006; 42: 24-30.
28. Zhuang SH, Agrawal M, Edgerly M et al. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005; 103: 1932-1938.
29. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy. Clin Pharmacokinet 2003; 42: 665-685.